Market Overview - The S&P 500 closed down approximately 39 to 40 points, reflecting a decline of about 0.6%, while the Dow lost nearly 800 points or about 1.6% [7] - The Nasdaq composite decreased by about 60 points, equating to a drop of 0.25%, and the Russell 2000 fell by about 50 points or 1.9% [7] - A total of 365 names in the S&P 500 were lower, with only 137 gaining ground, indicating a broad market decline [8] Sector Performance - Among sectors, three finished in the green while eight were in the red, with technology up by about 0.4% and energy leading with a gain of about 0.6% [8] - Consumer staples saw a decline of approximately 2.4% [9] Notable Stocks - Booking Holdings was the top gainer on the Nasdaq 100, increasing by about 8.5%, as Mizuho upgraded its recommendation based on expectations of a relief rally [11][12] - Broadcom's stock rose by about 4.8% following a quarterly update that exceeded expectations, with the CEO projecting AI chip sales to surpass $100 billion next year [14] - Marvell Technology reported earnings of $0.80 per share, beating estimates by a penny, with revenue of $2.22 billion aligning with expectations, leading to a 6% stock increase [22][24] Company-Specific Developments - Nvidia and AMD stocks were negatively impacted by news that the U.S. is considering requiring permits for global chip sales, although Nvidia's stock later recovered [4][5] - Roche Holding's shares fell by 6.3% after disappointing results from an experimental obesity treatment compared to a competitor's drug [18] - A ticket reseller's shares dropped by 12.4% due to a forecast and quarterly results that fell short of Wall Street estimates, attributed to a lack of major events boosting sales [19][20] - UPS was on track to close with a market value below FedEx for the first time, reflecting investor concerns about its long-term growth trajectory [21]

Novo Nordisk shares are bouncing back from their worst ever year, with bulls hoping that a pill version of its blockbuster obesity shot will help finally turn things around for the Danish drugmaker https://t.co/7Mss4FsUoj ...

Elsewhere in the next generation. Obesity shot by Eli Lilly helped patients lose almost a quarter of their body weight. In a recent study, the drug was so effective that some patients dropped out of the study because they lost so much weight.Bloomberg health reporter Madison Muller joins us to explain. Madison just how big of a step up is this in progress for these weight loss medications. Yeah.This is a huge step up. That's exactly right. I mean, this is the next wave of therapeutics, the next generation o ...

Roche will move an experimental obesity shot into late-stage trials next year in a bid to challenge leaders in the booming market https://t.co/u9HJHC59Ph ...

Lily is raising the list price for its obesity shot in the UK, as the pharma industry comes under pressure from Trump to increase medicine prices in Europe and lower them for Americans https://t.co/8o5bDXYIW0 ...